Acuity Brands board changes: Peter C. Browning retires, Mark J. Sachleben elected effective Aug 6, 2021

ACUITY INC. (DE)

Peter C. Browning retired from Board on August 6, 2021, after 20 years of service including as Lead Director.
Mark J. Sachleben, CFO of New Relic (NYSE: NEWR), elected to Board effective same date; term expires at next annual meeting.
Sachleben appointed to Governance Committee and Compensation and Management Development Committee.
Received one-time restricted stock award valued at $20,000 vesting ratably over three years.
Standard indemnification agreement entered into with Sachleben.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mark J. Sachleben

Director

AYI · ACUITY INC. (DE)

Effective: 2021-08-06
Filed: August 10, 2021, 7:59 PM ET

the election of Mark J. Sachleben to the Board

Departed

Peter C. Browning

Director

AYI · ACUITY INC. (DE)

Effective: 2021-08-06
Filed: August 10, 2021, 7:59 PM ET

the retirement of Peter C. Browning from the Company’s Board of Directors

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Mark J. Sachleben was elected as Director at ACUITY INC. (DE).

Action: elected
Role: Director

Exact text from the filing

the election of Mark J. Sachleben to the Board

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Peter C. Browning retired as Director at ACUITY INC. (DE).

Action: retired
Role: Director

Exact text from the filing

the retirement of Peter C. Browning from the Company’s Board of Directors

View on SEC.gov

ACUITY INC. (DE) filing history →

Source: SEC EDGAR

accession 0001144215-21-000070

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.